HC Wainwright Has Bullish Outlook for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - HC Wainwright increased their FY2024 earnings estimates for shares of Compass Therapeutics in a report released on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.36) per share for the year, up from their previous estimate of ($0.42). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Compass Therapeutics' Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.09 EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03.

A number of other equities research analysts also recently issued reports on the stock. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a report on Monday, September 16th. Leerink Partners cut shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $5.00 to $4.00 in a research note on Friday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th.

Compass Therapeutics Trading Down 10.1 %

Shares of NASDAQ CMPX traded down $0.16 on Friday, reaching $1.43. 346,663 shares of the company traded hands, compared to its average volume of 433,759. The stock has a market capitalization of $196.75 million, a PE ratio of -4.30 and a beta of 0.92. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The company has a 50 day moving average of $1.76 and a 200 day moving average of $1.42.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently bought and sold shares of the business. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the 3rd quarter valued at $25,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics in the third quarter valued at about $30,000. SG Americas Securities LLC raised its position in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after purchasing an additional 5,515 shares during the period. Bleakley Financial Group LLC acquired a new position in shares of Compass Therapeutics during the first quarter worth about $80,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the second quarter worth about $41,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.